Shift Bioscience

The company raised $16m seed funding in October in a round led by BGF with existing investors F-Prime Capital, Kindred Capital and Abcam co-founder and serial investor Jonathan Milner participating.

Shift will use the seed funding to accelerate the development of its AI cell simulation platform, enabling the identification of novel genes for safe rejuvenation of cells indicated in age-related illnesses. The funding will also support the development of an IP portfolio for the novel rejuvenation genes identified by the business.